Clinical management of pain in advanced lung cancer

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 331-346

  Simmons, Claribel P L ^a   MacLeod, Nicholas ^a   Laird, Barry J A ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Analgesia; Lung cancer; Pain management

Indexed keywords

17 METHYLNALTREXONE; AMITRIPTYLINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CODEINE; CODEINE PHOSPHATE; DEXAMETHASONE; DULOXETINE; FENTANYL; GABAPENTIN; HYDROMORPHONE; IBUPROFEN; IMIPRAMINE; KETAMINE; LAXATIVE; METHADONE; MORPHINE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OXYCODONE; PARACETAMOL; PREGABALIN; TAPENTADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADVANCED CANCER; ALLODYNIA; ALTERNATIVE MEDICINE; BONE METASTASIS; BRAIN METASTASIS; BREAKTHROUGH PAIN; CANCER PAIN; CANCER RADIOTHERAPY; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED DRUG RELEASE; CORDOTOMY; DIABETIC NEUROPATHY; DISTRESS SYNDROME; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG METABOLISM; DYSPNEA; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERALGESIA; INTRACTABLE PAIN; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NERVE BLOCK; NEUROPATHIC PAIN; NEUROTOXICITY; NIGHTMARE; NOCICEPTION; NOCICEPTIVE PAIN; OSTEOARTHROPATHY; PAIN; PANCOAST TUMOR; PATHOPHYSIOLOGY; PLEURA EFFUSION; POSTHERPETIC NEURALGIA; PSEUDOHALLUCINATION; RESPIRATION DEPRESSION; REVIEW; RHIZOTOMY; SOMNOLENCE; SPINAL CORD STIMULATION; THORAX DISEASE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VIVID DREAM;

EID: 84867494827     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S8360     Document Type: Review

References (141)

1. GLOBOCAN. European age-standardized rates calculated by the Statistical Information Team at cancer research UK. 2011.
2. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. Pain. 1999;82(32):263-74.
3. Cooley ME. Symptoms in adults with lung cancer. A systematic research review. J Pain Symptom Manage. 2000;19(2):137-53.
4. Laird BJ, Scott AC, Colvin LA, et al. Pain, depression, and fatigue as a symptom cluster in advanced cancer. J Pain Symptom Manage. 2011;42(1):1-11.
5. Laird BJ, Walley J, Murray GD, Clausen E, Colvin LA, Fallon MT. Characterization of cancer-induced bone pain: an exploratory study. Support Care Cancer. 2011;19(9):1393-401.
6. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8): 733-42.
7. Grippi MA. Clinical aspects of lung cancer. Semin Roentgenol. 1990;25(1); 25:12-24.
8. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain. 1979;6(3):249.
9. Carr DB, Goudas LC. Acute pain. Lancet. 1999;353(9169):2051-8.
10. Ferrell BR, Juarez G, Borneman T. Use of routine and breakthrough analgesia in home care. Oncol Nurs Forum. 1999;26(10):1655-61.
11. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236-47.
12. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273-81.
13. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-34.
14. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag. 2010;6(2): 109-16.
15. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag. 2010;6(2):97-108.
16. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999; 353(9165):1695-700.
17. Stute P, Soukup J, Menzel M, Sabatowski R, Grond S. Analysis and treatment of different types of neuropathic cancer pain. J Pain Symptom Manage. 2003;26(6):1123-31.
18. Watson PN, Evans RJ. Intractable pain with lung cancer. Pain. 1987;29(2): 163-73.
19. Geneva W. World Health Organisation. Cancer Pain Relief. 1996.
20. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84(5): 587-93.
21. Radha Krishna LK, Poulouse JV, Tan BS, Goh C. Opioid use amongst cancer patients at the end of life. Ann Acad Med Singapore. 2010;39(10):790-7.
22. Krajnik M. Opioids affect inflammation and the immune system. Pain reviews. 1998;5:147-54.
23. Donnelly S, Davis MP, Walsh D, Naughton M. Morphine in cancer pain management: a practical guide. Support Care Cancer. 2002;10(1):13-35.
24. Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing. conversion dilemmas. J Pain Symptom Manage. 2001;21(5):397-406.
25. Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998;16(10):3222-9.
26. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002:CD003447.
27. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain. 1988;333:313-22.
28. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80(3):460-5.
29. Fickel J, Bagnol D, Watson SJ, Akil H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res. 1997;46(1-2):1-8.
30. McKay JS, Linaker BD, Turnberg LA. Influence of opiates on ion transport across rabbit ileal mucosa. Gastroenterology. 1981;80(2):279-84.
31. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16(4):383-94.
32. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16 Suppl 2:17-28.
33. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14(8):781-3.
34. Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr Med Res Opin. 2010;26(7): 1677-84.
35. Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med. 2000;14(2):111-9.
36. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322(7295):1154-8.
37. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother. 2007;41(6):984-93.
38. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503-12.
39. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;3:CD004847.
40. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3): 237-51.
41. Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain. 2000;16(2 Suppl):S49-55.
42. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-18.
43. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42(2):135-44.
44. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992;52(5):547-52.
45. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60(8):1284-9.
46. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9(5):571-91.
47. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural Clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain. 1995;61(3):391-9.
48. Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42(6):470-82.
49. Backonja MM. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain. 2000;16(2 Suppl):S67-72.
50. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557-66.
51. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible-and fixeddose regimens. Pain. 2005;115(3):254-63.
52. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274-83.
53. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebocontrolled trial. Pain. 2004;110(3):628-38.
54. Hugel H, Ellershaw JE, Dickman A. Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage. 2003;26(6):1073-4.
55. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001;429(1-3):71-8.
56. Jackson K, Ashby M, Martin P, Pisasale M, Brumley D, Hayes B. "Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage. 2001;22(4):834-42.
57. Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2003;1:CD003351.
58. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000; 60(6):1303-14.
59. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8):1729-43.
60. Stow PJ, Glynn CJ, Minor B. EMLA cream in the treatment of post-herpetic neuralgia. Efficacy and pharmacokinetic profile. Pain. 1989;39(3):301-5.
61. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain. 2008;24(2):142-54.
62. Jones VM, Moore KA, Peterson DM. Capsaicin 8% topical patch (Qutenza)-a review of the evidence. J Pain Palliat Care Pharmacother. 2011;25(1):32-41.
63. Vranken JH, Zuurmond WW, de Lange JJ. Continuous brachial plexus block as treatment for the Pancoast syndrome. Clin J Pain. 2000;16(4): 327-33.
64. Amesbury B, O'Riordan J, Dolin S. The use of interpleural analgesia using bupivacaine for pain relief in advanced cancer. Palliat Med. 1999;13(2): 153-8.
65. Wong FC, Lee TW, Yuen KK, Lo SH, Sze WK, Tung SY. Intercostal nerve blockade for cancer pain: effectiveness and selection of patients. Hong Kong Med J. 2007;13(4):266-70.
66. Doyle D. Nerve blocks in advanced cancer. Practitioner. 1982;226(1365): 539, 541-4.
67. Baker L, Lee M, Regnard C, Crack L, Callin S. Evolving spinal analgesia practice in palliative care. Palliat Med. 2004;18(6):507-15.
68. Williams JE, Louw G, Towlerton G. Intrathecal pumps for giving opioids in chronic pain: a systematic review. Health Technol Assess. 2000;4(32): iii-iv, 1-65.
69. Mueller-Schwefe G, Hassenbusch SJ, Reig E. Cost effectiveness of intrathecal therapy for pain. Neuromodulation. 1999;2:77-87.
70. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040-9.
71. Crul BJ, Blok LM, van Egmond J, van Dongen RT. The present role of percutaneous cervical cordotomy for the treatment of cancer pain. J Headache Pain. 2005;6(1):24-9.
72. Stuart G, Cramond T. Role of percutaneous cervical cordotomy for pain of malignant origin. Med J Aust. 1993;158(10):667-70.
73. Sanders M, Zuurmond W. Safety of unilateral and bilateral percutaneous cervical cordotomy in 80 terminally ill cancer patients. J Clin Oncol. 1995; 13(6):1509-12.
74. Patt RB, Reddy S. Spinal neurolysis for cancer pain: indications and recent results. Ann Acad Med Singapore. 1994;23(2):216-20.
75. Myers DP, Lema MJ, de Leon-Casasola OA, Bacon DR. Interpleural analgesia for the treatment of severe cancer pain in terminally ill patients. J Pain Symptom Manage. 1993;8(7):505-10.
76. McKenzie AG, Mathe S. Interpleural local anaesthesia: anatomical basis for mechanism of action. Br J Anaesth. 1996;76(2):297-9.
77. Scheinin B, Lindgren L, Rosenberg PH. Treatment of post-thoracotomy pain with intermittent instillations of intrapleural bupivacaine. Acta Anaesthesiol Scand. 1989;33(2):156-9.
78. Kambam JR, Hammon J, Parris WC, Lupinetti FM. Intrapleural analgesia for post-thoracotomy pain and blood levels of bupivacaine following intrapleural injection. Can J Anaesth. 1989;36(2):106-9.
79. Schneider RF, Villamena PC, Harvey J, Surick BG, Surick IW, Beattie EJ. Lack of efficacy of intrapleural bupivacaine for postoperative analgesia following thoracotomy. Chest. 1993;103(2):414-6.
80. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg. 2003;98(1 Suppl):21-30.
81. Marcy PY, Palussiere J, Descamps B, et al. Percutaneous cementoplasty for pelvic bone metastasis. Support Care Cancer. 2000;8(6):500-3
82. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123(Suppl 1): 137S-46.
83. Ripamonti C, Fulfaro F. Malignant bone pain: pathophysiology and treatments. Curr Rev Pain. 2000;4(3):187-96.
84. Urch C. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med. 2004;18(4):267-74.
85. Chow E, Harris K, Fan G, Tsao M, Sze WM, Wu J. Meta-analysis of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2007;19:S26. *** i could not find this exact article, although several were close in name/date/etc.
86. Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986;6(4): 247-55.
87. Hoskin PJ, Yarnold JR, Roos DR, Bentzen S. Radiotherapy for bone metastases. Clin Oncol (R Coll Radiol). 2001;13(2):88-90.
88. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798-804.
89. Kvale PA, Selecky PA, Prakash UB. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132 (Suppl 3):368S-403.
90. Jacofsky DJ, Haidukewych GJ. Management of pathologic fractures of the proximal femur: state of the art. J Orthop Trauma. 2004;18(7):459-69.
91. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005;10:52-62.
92. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletalrelated events in patients with bone metastases from lung cancer. Oncology. 2004;67(5-6):390-6.
93. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-7.
94. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol. 2005;75(3):258-70.
95. Chute CG, Greenberg ER, Baron J, Korson R, Baker J, Yates J. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer. 1985;56(8):2107-11.
96. Hogan Q, Haddox JD, Abram S, Weissman D, Taylor ML, Janjan N. Epidural opiates and local anesthetics for the management of cancer pain. Pain. 1991;46(3):271-9.
97. Parker C, Neville E. Lung cancer * 8: Management of malignant mesothelioma. Thorax. 2003;58(9):809-13.
98. Rosomoff HL, Brown CJ, Sheptak P. Percutaneous radiofrequency cervical cordotomy: technique. J Neurosurg. 1965;23(6):639-44.
99. Jackson MB, Pounder D, Price C, Matthews AW, Neville E. Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax. 1999;54(3):238-41.
100. Newman SJ, Hansen HH. Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974;33(2):492-6.
101. Thatcher N, Jayson G, Bradley B, Ranson M, Anderson H. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Semin Oncol. 1997;24(3 Suppl 8):S8-6-12.
102. Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58 Suppl 2:ii29-38.
103. Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol. 2004;23(4):330-2.
104. Berger A DE, Mercadante S, Oster G. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care (Engl). 2005;15(2):138-45.
105. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965; 150(3699):971-9.
106. Linderoth B, Gazelius B, Franck J, Brodin E. Dorsal column stimulation induces release of serotonin and substance P in the cat dorsal horn. Neurosurgery. 1992;31(2):289-96; discussion 96-7.
107. Stiller CO, Linderoth B, O'Connor WT, et al. Repeated spinal cord stimulation decreases the extracellular level of gamma-aminobutyric acid in the periaqueductal gray matter of freely moving rats. Brain Res. 1995;699(2):231-41.
108. Yakovlev AE, Resch BE, Karasev SA. Treatment of cancer-related chest wall pain using spinal cord stimulation. Am J Hosp Palliat Care. 2010; 27(8):552-6.
109. Barbera L, Zhang-Salomons J, Huang J, Tyldesley S, Mackillop W. Defining the need for radiotherapy for lung cancer in the general population: a criterion-based, benchmarking approach. Med Care. 2003;41(9): 1074-85.
110. Toy E, Macbeth F, Coles B, Melville A, Eastwood A. Palliative thoracic radiotherapy for non-small-cell lung cancer: a systematic review. Am J Clin Oncol. 2003;26(2):112-20.
111. Clinical practice guidelines for the treatment of unresectable non-smallcell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15(8):2996-3018.
112. Evans N, Palmer A. Controlling breakthrough pain in palliative care. Nurs Stand. 1998;13(7):53-4.
113. Brundage MD, Bezjak A, Dixon P, et al. The role of palliative thoracic radiotherapy in non-small cell lung cancer. Can J Oncol. 1996;6 Suppl 1: 25-32.
114. Langendijk JA, ten Velde GP, Aaronson NK, de Jong JM, Muller MJ, Wouters EF. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2000;47(1):149-55.
115. Simpson JR, Francis ME, Perez-Tamayo R, Marks RD, Rao DV. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys. 1985;11(4): 751-8.
116. Teo P, Tai TH, Choy D, Tsui KH. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1988;14(5):867-71.
117. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer. 1991;63(2):265-70.
118. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1992;65(6):934-41.
119. Abratt RP, Shepherd LJ, Salton DG. Palliative radiation for stage 3 nonsmall cell lung cancer-a prospective study of two moderately high dose regimens. Lung Cancer. 1995;13(2):137-43.
120. Macbeth FR, Bolger JJ, Hopwood P, et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol). 1996;8(3):167-75.
121. Rees GJ, Devrell CE, Barley VL, Newman HF. Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol). 1997; 9(2):90-5.
122. Nestle U, Nieder C, Walter K, et al. A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys. 2000;48(1):95-103.
123. Bezjak A, Dixon P, Brundage M, et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002;54(3): 719-28.
124. Sundstrom S, Bremnes R, Aasebo U, et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol. 2004;22:801-10.
125. Erridge SC, Gaze MN, Price A, et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol). 2005;17(1):61-7.
126. Lester JF, Macbeth FR, Toy E, Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev. 2006;(4): CD002143.
127. Kepka L, Olszyna-Serementa M. Palliative thoracic radiotherapy for lung cancer. Expert Rev Anticancer Ther. 2010;10(4):559-69.
128. Cardona AF, Reveiz L, Ospina EG, Ospina V, Yepes A. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2008;2:CD004284.
129. Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK. The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review. Brachytherapy. 2006;5:189-202.
130. Jeremic B, Videtic GM. Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys. 2011;80(4):969-77.
131. Tang JI, Shakespeare TP, Lu JJ, et al. Patients' preference for radiotherapy fractionation schedule in the palliation of symptomatic unresectable lung cancer. J Med Imaging Radiat Oncol. 2008;52(5):497-502.
132. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90(8):611-6.
133. Mercadante S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain. 1999;79(1):1-13.
134. Silvestri GA, Sherman C, Williams T, Leong SS, Flume P, Turrisi A. Caring for the dying patient with lung cancer. Chest. 2002;122(3):1028-36.
135. Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage. 2000;19(5):357-62.
136. Smith EL, Hann DM, Ahles TA, et al. Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer. J Pain Symptom Manage. 2001;21(4):323-9.
137. Targ EF, Levine EG. The efficacy of a mind-body-spirit group for women with breast cancer: a randomized controlled trial. Gen Hosp Psychiatry. 2002;24(4):238-48.
138. Deng G, Cassileth BR, Yeung KS. Complementary therapies for cancerrelated symptoms. J Support Oncol. 2004;2(5):419-26; discussion 27-9.
139. Paltiel O, Avitzour M, Peretz T, et al. Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol. 2001; 19(9):2439-48.
140. Jacobson JS, Workman SB, Kronenberg F. Research on complementary/ alternative medicine for patients with breast cancer: a review of the biomedical literature. J Clin Oncol. 2000;18(3):668-83.
141. Cassileth BR, Deng GE, Gomez JE, Johnstone PA, Kumar N, Vickers AJ. Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(Suppl 3):340S-54.